Focal S100A4 protein expression is an independent predictor of development of metastatic disease in cystectomized bladder cancer patients
- PMID: 16632178
- DOI: 10.1016/j.eururo.2006.02.027
Focal S100A4 protein expression is an independent predictor of development of metastatic disease in cystectomized bladder cancer patients
Abstract
Objective: The prognosis of patients with apparently localized, operable, muscle-invasive bladder cancer depends to a large extent on the presence or absence of subclinical, microscopic distant metastases at the time of surgery. Expression of the S100A4 protein has been shown to correlate with the risk of metastasis in both animal tumour-model systems and clinical investigations in other tumour types. The purpose of the present study was to investigate the prognostic potential of S100A4 protein expression for predicting distant metastatic relapse in muscle-invasive bladder cancer.
Methods: We analyzed 108 consecutive patients, treated for transitional cell bladder cancer with preoperative radiotherapy and cystectomy. Pretherapeutic biopsies of the bladder tumours were investigated for immunohistochemical expression of S100A4 protein and results, along with clinical and histopathological data, compared with the pattern of relapses over a 10+ yr follow-up period.
Results: Focal S100A4 protein expression emerged as the only significant independent predictor of distant metastatic relapse and distant metastasis-free survival in multivariate analysis.
Conclusion: There is a potential role for this marker in denoting patients with high or low risk of distant relapse independent of clinical stage and grade.
Comment in
-
Foreseeing cancer metastases.Eur Urol. 2006 Oct;50(4):648-9. doi: 10.1016/j.eururo.2006.03.054. Epub 2006 Apr 7. Eur Urol. 2006. PMID: 16626857 No abstract available.
Similar articles
-
Combined expression of S100A4 and Annexin A2 predicts disease progression and overall survival in patients with urothelial carcinoma.Urol Oncol. 2014 Aug;32(6):798-805. doi: 10.1016/j.urolonc.2014.02.009. Epub 2014 Jun 23. Urol Oncol. 2014. PMID: 24968947
-
Prognostic significance of heme oxygenase-1, S100 calcium-binding protein A4, and syndecan-1 expression in primary non-muscle-invasive bladder cancer.Hum Pathol. 2014 Sep;45(9):1830-8. doi: 10.1016/j.humpath.2014.04.020. Epub 2014 May 15. Hum Pathol. 2014. PMID: 24957789
-
Expression of S100A2 and S100A4 predicts for disease progression and patient survival in bladder cancer.Urology. 2007 Sep;70(3):602-7. doi: 10.1016/j.urology.2007.04.007. Epub 2007 Aug 3. Urology. 2007. PMID: 17688917
-
Local recurrence after radical cystectomy for invasive bladder cancer: an analysis of predictive factors.Urology. 2004 Oct;64(4):744-8. doi: 10.1016/j.urology.2004.05.003. Urology. 2004. PMID: 15491713 Review.
-
[Partial cystectomy as treatment of infiltrating transitional carcinoma of the bladder].Actas Urol Esp. 1997 Jun;21(6):572-89. Actas Urol Esp. 1997. PMID: 9412191 Review. Spanish.
Cited by
-
S100A4: a common mediator of epithelial-mesenchymal transition, fibrosis and regeneration in diseases?J Mol Med (Berl). 2008 May;86(5):507-22. doi: 10.1007/s00109-007-0301-3. Epub 2008 Mar 6. J Mol Med (Berl). 2008. PMID: 18322670 Review.
-
Molecular factors regulating E-cadherin expression in urothelial bladder cancer and their correlations with the clinicopathological features.Mol Biol Rep. 2017 Aug;44(4):365-377. doi: 10.1007/s11033-017-4118-z. Epub 2017 Aug 14. Mol Biol Rep. 2017. PMID: 28808805
-
Low ANXA10 expression is associated with disease aggressiveness in bladder cancer.Br J Cancer. 2011 Oct 25;105(9):1379-87. doi: 10.1038/bjc.2011.404. Epub 2011 Oct 6. Br J Cancer. 2011. PMID: 21979422 Free PMC article.
-
[S100A4, a potential therapeutic target on bladder cancer stem cells].Nan Fang Yi Ke Da Xue Xue Bao. 2017 Jul 20;37(7):869-874. doi: 10.3969/j.issn.1673-4254.2017.07.03. Nan Fang Yi Ke Da Xue Xue Bao. 2017. PMID: 28736360 Free PMC article. Chinese.
-
Immunogenicity of HLA-A1-restricted peptides derived from S100A4 (metastasin 1) in melanoma patients.Cancer Immunol Immunother. 2009 Aug;58(8):1265-73. doi: 10.1007/s00262-008-0640-0. Epub 2009 Jan 13. Cancer Immunol Immunother. 2009. PMID: 19139886 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials